A modest pullback for U.S. stocks Friday eased the market from all-time highs and left major stock indexes on Wall Street in the red for the week. The S&P 500 closed 0.3% lower a day after ...

U.S. stocks are down in morning trading Friday, pulling the market back from all-time highs, as the Trump administration ...

In the highly regulated world of life sciences, quality isn’t a box to check—it’s a business imperative. For global en ...

Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

U.S. stocks are mostly lower in afternoon trading Friday, pulling the market back from all-time highs, as the Trump administration escalates its tariff threats against Canada.

This was the stock's second consecutive day of gains.

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need.

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds.